Lite Strategy, Inc. is a pharmaceutical company that develops novel cancer therapies by acquiring promising drug candidates and creating value through clinical development, strategic partnerships, and licensing arrangements. The company's approach focuses on evaluating cancer agents in combination with standard-of-care treatments to address resistance mechanisms and unmet medical needs. Historically, the company generated revenue through licensing agreements with pharmaceutical partners; it has transitioned toward exploring alternative strategies including digital asset initiatives while maintaining a pipeline of potential oncology drugs and ongoing nonclinical research activities.